Cpex Pharmaceuticals, Inc announced that its development and commercialization partner, Serenity Pharmaceuticals, has completed a phase-2a clinical study of an intranasal drug candidate delivered using Cpex's patented drug delivery platform technology for an undisclosed urology drug. During this study, 41 out of the 43 patients treated showed a positive response to treatment. Serenity has also completed an end-of-phase-2 meeting with the FDA.

"In less than a year, our partner Serenity has taken this urology drug candidate from the Investigational New Drug application stage through an end-of-phase-2 meeting," stated John Sedor, president and chief executive officer of CPEX Pharmaceuticals. "Serenity's continued commitment to rapid clinical development, in addition to the positive data collected in their clinical trials, make us optimistic as to the future potential of this drug candidate. In addition, this positive data, along with our ongoing progress with Nasulin, continue to validate the significant untapped potential of Cpex's permeation enhancement technology. We look forward to providing more detail at a future date as its development continues."

Serenity Pharmaceuticals is a privately held, Pennsylvania-based pharmaceutical development company.

Cpex Pharma is an emerging specialty pharmaceutical company focused on the development, licensing and commercialization of pharmaceutical products utilizing Cpex's validated drug delivery platform technology.